# Nanyang Ventures

> Nanyang Ventures is a VC fund in Sydney backing Biopharma, Health Care and Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Sydney, Australia
- Total investments: 1
- Last investment: Dec 2002
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.nanyangventures.com

Nanyang Ventures is a VC fund in Sydney focused on Biopharma and Health Care. Nanyang Ventures invests with the aim of building listable companies. Company spokesman John Mulquiney said the Genetic Solutions management team had been successful at commercialising the company's technology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 100% |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| QRxPharma | QRxPharma is an Australian-based, commercial-stage specialty pharmaceutical company focused on the development and commercialization of new pain management and abuse prevention productsBased on a development strategy that focuses on enhancing the clinical utility of currently approved compounds as well as bringing new products to market, thecompany's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes.In Q4 2013, the Company plans to refile with the US Food and Drug Administration a New Drug Application for its lead product candidate, immediate release MOXDUO®, for the treatment of acute pain. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc. and Aspen Group for the commercialisation of immediate release MOXDUO in the US, Canada, Australia (including New Zealand and Oceania) and South Africa.The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of MOXDUO. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology. | $5M | Series A | Dec 10, 2002 |  |

1 of 1 investments shown.

## Co-investors
- [Innovation Capital](https://shizune.co/investors/profile/innovation-capital) — VC Fund, 1 deal together
- [Spring Ridge Ventures](https://shizune.co/investors/profile/spring-ridge-ventures) — VC Fund, 1 deal together
- [Uniseed Ventures](https://shizune.co/investors/profile/uniseed-pty) — VC Fund, 1 deal together
- [Uniseed](https://shizune.co/investors/profile/uniseed-vc) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Biotech Investors in Australia](https://shizune.co/investors/biotech-investors-australia)
- [Biotech VC Funds in Australia](https://shizune.co/investors/biotech-vc-funds-australia)
- [Biotechnology VC Funds in Australia](https://shizune.co/investors/biotechnology-vc-funds-australia)

## FAQ

### What does Nanyang Ventures invest in?

Nanyang Ventures invests primarily in Biopharma, Health Care and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Nanyang Ventures last invest?

The most recent investment recorded for Nanyang Ventures closed in Dec 2002. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co